Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poziotinib in EGFR or HER2 Exon 20 Mutated NSCLC
NCT04044170Phase 2Terminated
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jul 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC), sponsored by Hanmi Pharmaceutical. Started Jul 2019; status: terminated.
02
Drugs
poziotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04044170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044170.